Cathy Belt on How to Act on Inherited Cancer Symptoms

Video

Cathy Belt, RN, MSN, AOCN, Abramson Cancer Center of the University of Pennsylvania, discusses possible steps individuals can take upon finding out they have an inherited cancer syndrome, such as mutations in the BRCA1 or BRCA2 genes.

Cathy Belt, RN, MSN, AOCN, Abramson Cancer Center of the University of Pennsylvania, discusses possible steps individuals can take upon finding out they have an inherited cancer syndrome, such as mutations in the BRCA1 or BRCA2 genes.

Surveillance is important to monitor for any early signs of cancer, including earlier and more frequent screening to identify any abnormalities before they become cancerous.

Related Videos
Related Content
dna genetics genomic tests © marina zlochin -adobe.stock.com.png

Out-of-Pocket Costs, Insurance Status May Impact Genomic Testing Rates

April 10th 2024
Article

Genetic testing decisions in patients with cancer may be affected by significant out-of-pocket costs.

lung cancer

Should You Wait for NGS Results Before Initiating NSCLC Treatment?

November 17th 2023
Article

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

Are At-Home Genomic Tests Such as 23andMe Ethical?

Are At-Home Genomic Tests Such as 23andMe Ethical?

September 22nd 2023
Article

Cheryl VerStrate, DNP, AGPCNP-BC, OCN, explains the pitfalls with at-home genomic tests and why nurses must be ready to talk to their patients about genetic counseling.

nurse with patient

Increase in Direct-to-Consumer Genomic Testing Yields New Ethical Considerations for Oncology Nurses

August 10th 2023
Article

Oncology nurses make the case for nurse intervention with direct-to-consumer genomic testing.

DNA

Oncology Nurses Play a Vital Role in Fostering Biomarker Testing Conversations With Patients

April 28th 2023
Article

Julie C. Martin DNP, AOCN, FNP-BC, discusses best practices to approaching conversations on clinically actionable genomic results with patients.

DNA Helix

CDCT1 Testing Study Highlights Pitfalls in Current NCCN Genetic Condition Screening Guidelines

April 18th 2023
Article

Findings from the TAPESTRY trial showed that approximately 40% of patients with genetic conditions may be missed by current NCCN guidelines.

© 2024 MJH Life Sciences

All rights reserved.